Brexit will be partly blamed by the UK’s fiscal watchdog for the gaping hole in the public finances at next month’s Budget, ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational study build on the strength of the data for amivantamab in ...

Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in ...